Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP9 | P55211 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133705 | 0.91 | PRKCI (0.50) | HTR7CYP2A6CDC7MAPTCYP1A2 | |
| SCHEMBL1098394 | 0.86 | CYP19A1 (0.51) | HTR7CYP2A6MAPTCYP1A2CYP19A1 | |
| SCHEMBL26697740 | 0.81 | ALDH1A1 (0.43) | HTR7CYP2A6MAPTTSHRALDH1A1 | |
| SCHEMBL29936240 | 0.81 | ALDH1A1 (0.43) | HTR7CYP2A6MAPTTSHRALDH1A1 | |
| SCHEMBL13940643 | 0.79 | CYP2A6 (0.47) | HTR7CYP2A6CDC7L3MBTL1 | |
| SCHEMBL15712293 | 0.79 | HTR7 (0.62) | HTR7CDC7MAPTCYP1A2CYP19A1 | |
| SCHEMBL27797963 | 0.79 | CDC7 (0.49) | HTR7CDC7MAPTCYP1A2TSHR | |
| SCHEMBL5150336 | 0.79 | CDC7 (0.49) | HTR7CDC7MAPTCYP1A2TSHR | |
| SCHEMBL16455706 | 0.78 | L3MBTL1 (0.56) | HTR7MAPTTSHRALDH1A1TDP1 | |
| SCHEMBL29613208 | 0.78 | L3MBTL1 (0.56) | HTR7MAPTTSHRALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-111164074-B | Heat shock protein 90 inhibitors | 台北医学大学 | 2024-02-02 | — | — | CN | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-117136184-A | Aminopyrimidine compounds and methods of use thereof | 泰拉生物科学公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116655599-A | Synthesis and application of EGFR allosteric inhibitors | 江南大学 | 2023-08-29 | — | — | CN | disclosed |
| US-20230115945-A1 | AMINOPYRIMIDINE COMPOUNDS | TYRA BIOSCIENCES, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-4085055-A1 | AMINOPYRIMIDINE COMPOUNDS | Tyra Biosciences, Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11479528-B2 | Heat shock protein 90 inhibitors | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-10-25 | — | — | US | disclosed |
| WO-2022182972-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| US-4403791-A | Carbonless duplicating and marking systems | STERLING DRUG INC. (US) | 1983-09-13 | — | — | US | disclosed |
| US-4377698-A | 2,4 Bis(2-indolyl-3)-4-oxobutanoic acids | STERLING DRUG INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351768-A | CARBONLESS, DUPLICATION, INDOLE DYES | STERLING DRUG INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4322352-A | Indolyl phthalide compounds | STERLING DRUG INC. (US) | 1982-03-30 | — | — | US | disclosed |
| US-4307018-A | CHROMOGENS FOR COPYING SYSTEMS | STERLING DRUG INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4275121-A | Carbonless duplicating and marking systems utilizing indolyl-substituted furanone color formers | STERLING DRUG INC. (US) | 1981-06-23 | — | — | US | disclosed |
| US-4257954-A | INDOLYL-PHENYLSULFONYL-PHENYL METHANE | STERLING DRUG INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4251446-A | COLOR PRECURSORS | STERLING DRUG INC. (US) | 1981-02-17 | — | — | US | disclosed |
| US-4189171-A | PRESSURE SENSITIVE, THERMAL AND HECTOGRAPHIC SYSTEMS | STERLING DRUG INC. (US) | 1980-02-19 | — | — | US | disclosed |
| US-4075224-A | 3,5-Bis (indolyl)-5-(indolyl)-2(5H)-furanones | STERLING DRUG INC. (US) | 1978-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230115945-A1 | AMINOPYRIMIDINE COMPOUNDS | FGFR2, FGFR1, FGFR4 | HTR7 3202/4885CYP2A6 3325/4885CDC7 624/4885 |
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HTR7 1182/4885CYP2A6 4206/4885CDC7 646/4885 |
| US-11479528-B2 | Heat shock protein 90 inhibitors | HSP90AB1, HSP90AB2P, HSP90AA1 | HTR7 2487/4885CYP2A6 3922/4885CDC7 450/4885 |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | HTR7 1199/4885CYP2A6 348/4885CDC7 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.